{"id":"W3156148127","doi":"10.1158/1078-0432.ccr-20-4746","title":"Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":348,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Adverse effect; Melanoma; Cancer; Antibody; Lung cancer; Gastroenterology; Oncology; Colorectal cancer; Ovarian cancer; Immunology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002062056,0.002085357,0.002091287,0.0004790139,0.0004764164,0.001179016,0.0008963511,0.001374172,0.003684193],"category_scores_gemma":[0.001004693,0.0007547526,0.001356912,0.0004005023,0.001210435,0.0009020916,0.0003474167,0.00427046,0.0009802646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001132292,"about_ca_system_score_gemma":0.002276726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009256098,"about_ca_topic_score_gemma":0.001459694,"domain_scores_codex":[0.9995104,0.0002488138,0.00002858913,0.00007840817,0.00004219606,0.00009158735],"domain_scores_gemma":[0.999148,0.0001188501,0.0001445927,0.00006794778,0.00006493498,0.0004556605],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8060346,0.09826834,0.003048629,0.000610101,0.001046823,0.0001530124,0.0001598526,0.003550315,0.03765296,0.0002865129,0.004088214,0.0451005],"study_design_scores_gemma":[0.6531481,0.3351765,0.003317362,0.00002822883,0.0002971158,0.0001224086,0.00002709264,0.001991759,0.004410711,0.0001827846,0.001280679,0.00001737288],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914732,0.001429314,0.000658202,0.0006094719,0.0001971937,0.002466033,0.0009154375,0.0001170238,0.002134161],"genre_scores_gemma":[0.988076,0.001198089,0.001903933,0.0008710675,0.0002234973,0.002634773,0.002342076,0.0000341462,0.002716421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003684193,"threshold_uncertainty_score":0.01232487,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1544985978344693,"score_gpt":0.553803520585191,"score_spread":0.3993049227507217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}